AIDS Therapies (Monoclonal Antibodies)

New Antibody May Block HIV Infection

Published in AIDS Weekly, May 10th, 1999

A recent study described the activity of PRO 140 (PA14) (Progenics Pharmaceuticals, Inc., Tarrytown, New York), a monoclonal antibody (MAb) with potent anti-HIV activity.

The study, published in the Journal of Virology (May 1999;73(5):4145-4155), was conducted in collaboration with the Aaron Diamond AIDS Research Center (ADARC) in New York.

PRO 140 targets CCR5, a protein expressed on the surface of certain immune system cells that provide targets for HIV infection. In 1996, researchers at Progenics and ADARC identified the human protein CCR5 to be a co-receptor required for HIV isolates to fuse with and infect target cells. Individuals who...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1999-05-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry